Grifols has reinforced its position in the American market (especially Canada) with the acquisition of plasma fractionation (in Canada) and plasma collection (in the US) facilities from the South-Korean-based Green Cross Pharma, for €402m. While this deal would reduce Grifol’s reliance on third-parties for plasma-sourcing, liquidity could come under pressure with the net-debt/EBITDA ratio rising to 4.7x. Nonetheless, the Spanish pharma should be able to finance the deal internally
21 Jul 2020
Plasma self-sufficiency at the cost of the balance sheet (?)
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Plasma self-sufficiency at the cost of the balance sheet (?)
Grifols, S.A. Class A (GRF:WBO) | 0 0 1.0% | Mkt Cap: 14,874m
- Published:
21 Jul 2020 -
Author:
Rishabh Kochar -
Pages:
2
Grifols has reinforced its position in the American market (especially Canada) with the acquisition of plasma fractionation (in Canada) and plasma collection (in the US) facilities from the South-Korean-based Green Cross Pharma, for €402m. While this deal would reduce Grifol’s reliance on third-parties for plasma-sourcing, liquidity could come under pressure with the net-debt/EBITDA ratio rising to 4.7x. Nonetheless, the Spanish pharma should be able to finance the deal internally